Lung Carcinoid Tumor
7
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
14.3%
1 terminated out of 7 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Bronchoscopic Laser Ablation of Peripheral Lung Tumors
Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers
Active Surveillance in Early Lung Cancer
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery